Figure 1. Research Method Flow Chart 10
Figure 2. Breakdown of Primary Research 12
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 14
Figure 4. Europe Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 16
Figure 5. Europe Biodefense Market, 2019-2030, $ mn 18
Figure 6. Primary Drivers and Impact Factors of Europe Biodefense Market 19
Figure 7. Primary Restraints and Impact Factors of Europe Biodefense Market 22
Figure 8. Investment Opportunity Analysis 26
Figure 9. Porter’s Fiver Forces Analysis of Europe Biodefense Market 29
Figure 10. Breakdown of Europe Biodefense Market by Product, 2019-2030, % of Sales Revenue 33
Figure 11. Europe Addressable Market Cap in 2020-2030 by Product, Value ($ mn) and Share (%) 34
Figure 12. Europe Biodefense Market: Vaccines, 2019-2030, $ mn 35
Figure 13. Europe Biodefense Market: Anthrax, 2019-2030, $ mn 38
Figure 14. Europe Biodefense Market: Smallpox, 2019-2030, $ mn 39
Figure 15. Europe Biodefense Market: Botulism, 2019-2030, $ mn 40
Figure 16. Europe Biodefense Market: Nuclear/Radiation, 2019-2030, $ mn 41
Figure 17. Europe Biodefense Market: E-Bola, 2019-2030, $ mn 42
Figure 18. Europe Biodefense Market: Zika, 2019-2030, $ mn 43
Figure 19. Europe Biodefense Market: Other Vaccines, 2019-2030, $ mn 44
Figure 20. Europe Biodefense Market: Biothreat Detection Devices, 2019-2030, $ mn 45
Figure 21. Europe Biodefense Market: Antibiotics, 2019-2030, $ mn 47
Figure 22. Europe Biodefense Market: Masks, 2019-2030, $ mn 48
Figure 23. Europe Biodefense Market: Other Products, 2019-2030, $ mn 49
Figure 24. Breakdown of Europe Biodefense Market by Sales Channel, 2019-2030, % of Sales Revenue 50
Figure 25. Europe Addressable Market Cap in 2020-2030 by Sales Channel, Value ($ mn) and Share (%) 51
Figure 26. Europe Biodefense Market: Online Sales, 2019-2030, $ mn 52
Figure 27. Europe Biodefense Market: Offline Sales, 2019-2030, $ mn 53
Figure 28. Breakdown of Europe Market by Application, 2019-2030, % of Revenue 54
Figure 29. Europe Addressable Market Cap in 2020-2030 by Application, Value ($ mn) and Share (%) 55
Figure 30. Europe Biodefense Market: Military, 2019-2030, $ mn 56
Figure 31. Europe Biodefense Market: Civilian, 2019-2030, $ mn 57
Figure 32. Breakdown of European Biodefense Market by Country, 2019 and 2030, % of Revenue 59
Figure 33. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 60
Figure 34. Biodefense Market in Germany, 2019-2030, $ mn 61
Figure 35. Biodefense Market in UK, 2019-2030, $ mn 63
Figure 36. Biodefense Market in France, 2019-2030, $ mn 65
Figure 37. Biodefense Market in Spain, 2019-2030, $ mn 67
Figure 38. Biodefense Market in Italy, 2019-2030, $ mn 69
Figure 39. Biodefense Market in Russia, 2019-2030, $ mn 71
Figure 40. Biodefense Market in Rest of Europe, 2019-2030, $ mn 73
Figure 41. Growth Stage of Europe Biodefense Industry over the Forecast Period 75
Europe biodefense market reached $1,151.8 million in 2019 and will grow by 8.5% annually over 2020-2030 owing to the rising need for biodefense agents and equipment in the region.
Highlighted with 35 tables and 41 figures, this 109-page report “Europe Biodefense Market 2020-2030 by Product (Vaccines, Detection Devices, Antibiotics, Masks), Sales Channel, Application (Military, Civilian), and Country: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire Europe biodefense market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
• Market Structure
• Growth Drivers
• Restraints and Challenges
• Emerging Product Trends & Market Opportunities
• Porter’s Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify Europe biodefense market in every aspect of the classification from perspectives of Product, Sales Channel, Application, and Country.
Based on Product, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
Vaccines
• Anthrax
• Smallpox
• Botulism
• Nuclear/Radiation
• E-Bola
• Zika
• Other Vaccines
Biothreat Detection Devices
• Detectors/Triggering Devices
• Assays and Reagents
• Samplers
• Identifiers
Antibiotics
Masks
Other Products
Based on Sales Channel, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Online Sales
• Offline Sales
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.
• Military
• Civilian
Geographically, the following national/local markets are fully investigated:
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe (further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)
For each aforementioned country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Product, Sales Channel, and Application over the forecast years is also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Specifically, potential risks associated with investing in Europe biodefense market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.
Key Players (this may not be a complete list and extra companies can be added upon request):
Achaogen, Inc.
Alexeter Technologies LLC
Alnylam Pharmaceuticals, Inc.
Altimmune, Inc.
Bavarian Nordic AS
BioFactura, Inc.
Cleveland Biolabs, Inc.
Dynavax Technologies Inc
Dynport Vaccine Company LLC (DVC)
Elusys Therapeutics, Inc.
Emergent BioSolutions Inc
General Dynamics Corp.
GlaxoSmithKline Plc
Ichor Medical Systems
Mediimmune (AstraZeneca)
Nanotherapeutics, Inc.
Ology Bioscience
PathSensors Inc
Pluristem Therapeutics
Sanofi Pasteur Ltd.
SIGA Technologies, Inc.
Soligenix, Inc.
Xoma Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More